The market is driving prices on GLP-1 drugs down, and an added benefit is lower spending on food.

Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

Some patients reluctantly shifted to save money while others have appealed for coverage of Zepbound after having experienced ...

Eli Lilly and Novo Nordisk are actively exploring other medical uses for their GLP-1 drugs, and have already seen some ...

Thousands find weight loss relief on Zepbound. Now, they face a choice: Try a different medicine that may have adverse side effects or stop treatment.

Nearly two-thirds of patients who started on weight-loss drugs Wegovy or Zepbound last year were still taking them a year later, according to an analysis of U.S. pharmacy claims.

Novo Nordisk underestimated the impact of competition from personalized compounded drugs when providing sales estimates for ...

Zepbound led to an average weight loss of 20.2 percent compared to Wegovy's 13.7 percent. We talked with healthcare experts to understand the study's findings, what sets these drugs apart and how ...

Wegovy, like Zepbound, is FDA-approved for weight loss. Its main ingredient is semaglutide, which is also found in Ozempic, a medication that is approved by the FDA to treat Type 2 diabetes but is ...

Wegovy and Zepbound prices fall, but access to the obesity drugs still isn’t guaranteed The medications Wegovy and Zepbound still amount to around $500 per month for those without insurance ...

Zepbound contains the active ingredient tirzepatide, the same drug used in Lilly’s diabetes drug Mounjaro. Wegovy contains semaglutide, the drug also in Novo Nordisk’s diabetes drug Ozempic.

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging. Reduced monthly costs for uninsured patients still amount to around $500.